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We performed a retrospective study of 90 consecutive cases with inoperable carcinoma of the oesophagus treated with definitive
chemoradiation at a single cancer centre between 1995 and 2002. For the last 4 years, 73 patients have received therapy according to
an agreed protocol. This outpatient-based regimen involves four cycles of chemotherapy, cycles 3 and 4 given concurrently with
50Gy external beam radiotherapy (XRT) delivered in 25 fractions over 5 weeks. Cisplatin 60mgm
 2day
 1 is given every 3 weeks
together with continuous infusional 5-fluorouracil 300mgm
 2day
 1, reduced to 225mgm
 2day
 1 during the XRT. In all, 45 (50%)
patients suffered one or more WHO grade 3/4 toxicity, grade 3 in 93% cases. Patients received more than 90% of the planned
chemoradiation schedule. The median overall survival was 26 (15, 496) months, 51% (41, 64) and 26% (13, 52) surviving 2 and 5
years, respectively. Advanced stage, particularly T4 disease, was associated with a worse prognosis. Patients considered not suitable
for surgery for reasons other than their disease, mainly co-morbidity, had a significantly better outcome, median survival 40 (26,
496) months, 2- and 5-year survivals 67% (54, 84) and 32% (13, 79), respectively (Po0.001). This schedule is a feasible, tolerable
and effective treatment for patients with oesophageal cancer considered unsuitable for surgery.
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Carcinoma of the oesophagus is becoming more common in
Europe and North America. In the UK, there are 7000 new cases
per year, the eighth most common malignancy, and in some
regions it has become more common than gastric cancer (Scottish
Audit Group, 2002). Despite difficulties with categorising tumours
at the gastro-oesophageal junction, there has clearly been a
significant increase in the number of adenocarcinomas occurring
in the lower oesophagus and proximal stomach, probably as a
consequence of gastro-oesophageal reflux disease. Given that the
presenting symptoms commonly indicate advanced disease, it is
not surprising that the long-term outcome remains poor, just 10%
of patients surviving 5 years after diagnosis.
In the UK, if the disease appears resectable and patients are
sufficiently fit, surgery remains the mainstay of therapy. However,
despite better staging and improving perioperative care, the
outcome from this treatment remains poor, with 30–45% patients
surviving 2 years after radical resection (Kelsen et al, 1998; Medical
Research Council Oesophageal Cancer Working Group, 2002). The
proportion of patients for whom this treatment is selected varies in
different countries from 25 to 45% (Fok et al, 1994; Coia et al,
2000; Pye et al, 2001). This complex surgery is challenging for both
the surgeon and the patient; between 5 and 10% will die as a result
of an oesophagectomy and 30–40% will suffer significant post-
operative morbidity. In addition, those patients who relapse within
2 years seldom regain the quality of life they previously
experienced (Blazeby et al, 2000). Some improvement in these
figures may be possible with adjuvant therapy (Walsh et al, 1996;
Medical Research Council Oesophageal Cancer Working Group,
2002) and centralisation of services (NHS executive, 2001), but it is
clear that the majority of patients will not benefit from this
treatment.
Radical radiotherapy (RT), or chemoradiation (CRT), has lead
to long-term survival in some reported series, though it is not
absolutely clear how these patients were selected for nonsurgical
therapy (Sykes et al, 1998; Cooper et al, 1999). Using modern
techniques and regimens, these therapies have not been tested as
an alternative to surgery in prospective randomised trials, and
attempts to do so have been unsuccessful. Although heavily
weighted by the results from one trial, a systematic review
concludes that concurrent chemoradiation is superior to RT alone,
albeit at the expense of increased toxicity (Wong et al, 2003).
In South East Wales, since 1998, those patients not suitable for
surgery, but where the extent of disease can be covered in a radical
radiation field, have been considered for definitive chemora-
diotherapy (CRT). Patients were deemed not suitable for surgery
because of factors relating to their disease, usually infiltration of
tumour into other mediastinal organs, or co-morbidity, making
surgery unacceptably hazardous. This study assesses the outcome
for this group of patients.
PATIENTS AND METHODS
This is a retrospective study of 90 consecutive patients treated
between 1 March 1995 and 1 October 2002, who received definitive
CRT at the Velindre Cancer Centre. One patient was diagnosed and
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ltreated in 1995 and three in 1997, and, based on encouraging early
results at our centre and elsewhere, a further 86 patients were
treated between 1998 and 2002. All patients were discussed at
multidisciplinary meetings attended by one or more specialist
gastro-enterologists, radiologists, pathologists, surgeons, oncolo-
gists, palliative care and upper GI nurses. Patients were initially
seen by the surgical team and counselled regarding the risks and
likely success of an oesophagectomy. The reasons for patients not
receiving surgery are shown in Table 1. Where more than one
reason was given, the predominant factor is stated.
All patients were confirmed histologically to have oesophageal
carcinoma. Patients had disease starting at or below 17cm ab oral,
and included patients with Siewert types I and II gastro-
oesophageal junctional disease (Siewert et al, 1998), provided
there was less than 3cm disease below the squamo-columnar
junction.
For the purpose of this analysis, definitive CRT was defined by a
planned dose of external beam RT of X45Gy delivered with
chemotherapy, at least partly given concurrently. Over time
treatment regimens and techniques evolved but for the last 4
years all patients were managed according to an agreed protocol.
All patients had endoscopic evaluation and a CT scan of thorax
and upper abdomen, to exclude those with macroscopic metastatic
disease. All patients had an endoscopic ultrasound (EUS) to assess
locoregional disease, except for six, of whom five had malignant
stricturing which precluded EUS evaluation.
Physiological assessment included routine haematological and
biochemical assays. Renal function was assessed further by
calculating the glomerular filtration rate (GFR) using the EDTA
clearance method or using the Cockroft formula, when an EDTA
test was carried out if the predicted GFR was less than 60mlmin
 1
or where there was a 25% rise in the serum creatinine after
cisplatin treatment. Patients being considered for surgery under-
went echocardiograms or MUGA scans, lung function testing with
spirometry and arterial blood gas analysis.
Of the 90 patients, 73 received the current treatment protocol for
definitive CRT. This consists of four cycles of cisplatin and 5-
fluorouracil (5FU), cycles three and four being given concurrently
with 5 weeks of RT. The cisplatin is given at 60mgm
 2 (reduced to
60mg total dose, where GFR o60mlsmin
 1) as a day case on Day
1 of each of the three weekly cycles. Carboplatin (AUC¼5) is given
instead of cisplatin if the GFR is less than 40mlmin
 1 or if
significant neuro-/nephrotoxicity occurs during treatment. During
the neoadjuvant phase of treatment the 5FU is given as a
continuous infusion of 300mgm
 2day
 1, reduced to
225mgm
 2day
 1 during the RT, via a central venous catheter.
Patients are given prophylactic warfarin 1mgday
 1.
The RT dose is 50Gy in 25 fractions given over 5 weeks in two
treatment phases. Phase 1 is given with an anterior–posterior
parallel pair field arrangement giving 26–30Gy, according to the
normal tissue tolerance of the spinal cord, heart and lungs. The
remainder is given using an anterior and two posterior oblique,
three-field plan. The dose was prescribed to the ICRU 50 reference
point, usually being the mid-plane of opposed fields and central
axis intersection point of multiple fields.
The conformal planned target volume (PTV) is the EUS-defined
gross tumour volume (GTV), with a 2–3cm margin in all
directions. Both phases are planned early during the neoadjuvant
phase of therapy using a 3D Helax planning system. The GTV is
drawn directly onto the axial planning images using distances of
the defined primary and nodal disease ab oral and to the tracheal
bifurcation, taken as a reference point, derived from the EUS. The
fields are checked with a barium study in the simulator prior to
treatment. Portal films are taken during the first week of each
phase of treatment.
Patients are reviewed by an oncologist or dedicated radio-
grapher prior to the first day of the chemotherapy cycle, and
weekly during the chemoradiation, noting treatment-related acute
toxicities. The intent is to deliver this treatment in the outpatient
department, though some patients require admission for ‘hotel’
needs. Enteral or parenteral feeding is not routinely used.
Of the remaining 17 patients, 13 received the same regimen
without the neoadjuvant phase of chemotherapy, one patient the
above regimen omitting the 5FU, two received four cycles of
epirubicin, cisplatin and infusional 5FU prior to chemoradiation
and one patient received two cycles of mitomycin C, ifosfamide
and cisplatin, concurrently with 50Gy radiation in 20 fractions.
Following the completion of chemoradiation, a CT scan is
performed to establish a disease ‘baseline’ after treatment, though
comparison with scans prior to treatment are notoriously difficult
to interpret. Patients no longer undergo EUS, as this invasive
procedure does not accurately stage disease after CRT (Bowrey
et al, 1999). Thus for the purpose of this study, no attempt was
made to document the response rate, other than disease
progression, at this stage.
All patients are reviewed clinically at regular intervals, but do
not routinely undergo radiological or endoscopic surveillance.
This continues until death or for the purpose of this study until 31
January 2003, when all data were censored. Five patients have been
lost to follow-up and their data censored at their last clinical
review. Survival is calculated from the date of histological
diagnosis. The date of recurrence is taken as the date of the
confirmatory investigations used, usually CT scan or endoscopy,
or the date a clinical diagnosis of disease progression was made in
the absence of these.
STATISTICAL ANALYSIS
The data were collected from the Information System for Clinical
Organisations (ISCO) – a database and patient activity system
available in all Welsh hospitals, patient notes and the Welsh
Cancer Information and Surveillance Unit registry. Data were
analysed using SPlus 2000. The outcome was assessed using the
Kaplan–Meier and log-rank methods, and contingency tables were
analysed using w
2. The effect of clinical covariates was determined
using Cox regression. Summary statistics are quoted with the 95%
confidence intervals in parentheses.
RESULTS
Patient and disease characteristics
Outcome data were available on all 90 patients who received
definitive chemoradiation. The distribution of patient and disease
Table 1 Reasons given for patients not receiving surgery
Number (%)
Co-morbidity 50 (56%)
Cardiac 18
Pulmonary 15
Performance status 11
Other 6
Disease 38 (42%)
T4 (aorta) 16
T4 (trachea) 7
T4 (pleura) 4
Lymphadenopathy 7
Other 4
Patient choice 2 (2%)
In each case, the predominant reason has been accepted.
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lcharacteristics is shown in Table 2. The mean age of patients at
diagnosis was 64 years (range 41–78). In all, 25 patients were over
70 years of age. There was a slight predominance of males. The
median follow-up of the surviving patients was 19.6 months as of
31 January 2003 (range 4.7–95.8 months). A total of 45 patients
died during the period of study.
There were similar numbers of adenocarcinomas and squamous
cancers in this series. In six cases, due to poor differentiation of the
tumour, it was not possible to classify the type. In all, 49 tumours
(54%) were situated in the lower one-third of the oesophagus or
crossed the gastro-oesophageal junction. The average length of the
primary tumour was 6.9cm (range 2–13cm) and was X8cmin22
cases (24%).
Safety and toxicity
The majority of patients received the chemoradiation schedule as
prescribed, the commonest dose modifications being made to the
chemotherapy treatment. A total of 37% of patients required a dose
modification to the planned chemotherapy schedule. These were
usually minor dose modifications or delays, most commonly
resulting from 5FU-induced mucosal toxicity. Overall, the patients
received 94 and 93% of the planned cisplatin and 5FU, respectively.
Four patients were changed to carboplatin as a result of neuro-/
nephrotoxicity. Only six (7%) patients received less than the
prescribed dose of radiation or a delay of more than 1 week in their
RT treatment.
There were no deaths directly related to treatment, though five
patients died during or within 30 days of completing treatment due
to progressive disease. One patient had a suspected pulmonary
embolism but a post mortem was not carried out. Significant
toxicities are shown in Table 3. In all, 45 patients (50%) suffered
one or more WHO grade 3 or 4 toxicities, being grade 3 in 93% of
cases. Haematological toxicity occurred in 16 patients, the majority
being neither serious nor associated with admission to hospital.
Seven patients required blood transfusion. In 22 cases (37%),
patients experienced moderate/severe mucocutaneous toxicity as a
consequence of 5FU, which responded to appropriate dose
modifications.
In all, 17 patients required nonelective hospitalisation due to
treatment complications, most commonly for rehydration as a
result of dysphagia, electrolyte disturbance and mucosal toxicity.
In addition, 18 patients (20%) required enteral feeding as a result
of malignant dysphagia and five patients developed deep venous
thrombosis, which required anticoagulation.
During follow-up, nine (10%) patients developed nonmalignant
strictures requiring dilatation and four patients developed tracheo-
oesophageal fistulae, all of whom had a covered stent successfully
placed in the oesophagus. Three patients had a persistent
ulcerative oesophagitis and two a temporary radiation pneumoni-
tis, which settled with appropriate treatment.
Patient survival
As of 31 January 2003, 45 (50%) of patients were alive, 36 with no
evidence of disease progression. One patient has been lost to
follow-up. The median progression-free survival for the whole
group was 18 (9, 38) months.
The median overall survival on an intention to treat analysis was
26 (15, 496) months. For the whole series, the 2-, 3- and 5-year
survivals were 51% (41, 64), 45% (34, 59) and 26% (13, 52),
respectively (Figure 1). In general, patients fared less well with
more advanced disease, and in general the effect of stage was
significant (P¼0.024, Figure 2). The median survival of 20 patients
with stage I or II disease had not been reached (496 months), 78%
(62, 100) being alive after 2 years. However, there was no
significant difference in survival between patients with stage III
and IVa disease (P¼0.89; median survival times 15 (11, 453) and
26 (15, 447) months, respectively). In patients with T4 disease,
the overall survival was significantly worse than in those with non-
T4 (Po0.001, Figure 3).
In 38 patients where the extent of their disease determined that
the chance of a complete resection (R0) was too low, the median
Table 2 Distribution of patient and disease characteristics of 90
consecutive cases with oesophageal cancer treated with definitive
chemoradiation between 1995 and 2002
Number (%)
Age
o50 6 (7%)
50–65 44 (49%)
66–75 33 (36%)
475 7 (8%)
Sex
M 49 (54%)
F 41 (46%)
Morphology
Adenocarcinoma 42 (47%)
Squamous 43 (48%)
Other 5 (6%)
Stage
I/II (T1N0,T2-3N0, T1-2N1) 20 (22%)
III (T3N1, T4N0-1) 54 (60%)
IVa (M1a disease) 16 (18%)
Tumour site
Upper one-third 4 (4%)
Middle one-third 37 (41%)
Lower one-third 34 (38%)
Type 1 GO junction 12 (13%)
Type 2 GO junction 3 (3%)
Table 3 Significant (WHO grade 3/4) treatment toxicities sustained
during chemoradiation
Grade 3(%) Grade 4(%)
Haematological
Neutropaenia 8 2
Anaemia 5 1
Mucositis
Oral 12 0
Oesophageal 3 0
Palmar–plantar erythema 5 0
Gastrointestinal
Nausea 2 0
Diarrhoea 5 0
DVT
CVC-related 3 0
Non-CVC-related 2 0
Neuropathy 3 0
Lethargy/asthenia 3 1
Other 5 0
Total 56 4
CVC¼central venous catheter, DVT¼deep-vein thrombosis.
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lsurvival was 11 (10, 42) months, whereas, in the 52 cases where
patient-related factors precluded surgery, the survival was
significantly better, (Po0.001; median survival time 40 (26,
496) months). In the latter group, the 2- and 5-year survivals
were 67% (54, 84) and 32% (13, 79), respectively.
In a Cox regression model, none of the covariates age, sex,
histological type, the presence of M1a disease (coeliac lymphade-
nopathy associated with a tumour of the lower third of the
oesophagus) and nodal status were significantly associated with
outcome (P40.29). The only significant prognostic indicator was
the presence of T4 disease, when compared with T1–T3 (hazard
ratio¼3.21 (1.32, 7.81), P¼0.01). The reason for not having
surgery was excluded from the Cox model because this factor is
partly derived from the stage of disease, and, as would be expected,
the association between the two was highly significant (w
2¼37,
Poo0.001). Of those cases deemed to be unsuitable for surgery
because of their disease, 66% were T4.
Patterns of failure
In all, 49 (54%) patients developed progressive disease during the
period of study. A total of 17 patients (19%) had radiological or
clinical evidence of disease progression at the end of or just after
completion of treatment. In a further 21 cases (23%), disease
recurrence was confined to locoregional sites, defined as lying
within the planned RT target volume. In eight patients, the initial
relapse was at a distant site and in three both local and distant
disease progression occurred together.
Second-line treatment
The 49 patients who relapsed were considered for second-line
treatment, but in 23 (47%) best supportive care was deemed most
appropriate. Of 26 patients who received active second-line
palliative therapy, 22 (85%) underwent endoscopic therapy to
palliate local disease, this being the placement of an oesophageal
stent in 19 (73%) and laser therapy in three. For those patients who
had distant metastases as a component of disease relapse, five
(42%) underwent second-line chemotherapy. The median survival
of patients after disease progression was 5.1 (3.7, 13) months.
DISCUSSION
In this series, 90 patients with oesophageal cancer who received
definitive chemoradiation, having been selected for nonsurgical
therapy because of co-morbidity or locally advanced disease, had a
median survival of 26 months, 51 and 26% being alive 2 and 5
years, respectively, after diagnosis.
These results compare favourably with other published series
evaluating the use of chemoradiation for oesophageal cancer (Coia
et al, 1991; Cooper et al, 1999; Kaneko et al, 2003). The most
important of these, RTOG 85-01, was a US Intergroup randomised
controlled trial comparing chemoradiation with RT alone (Cooper
et al, 1999). In the final report, the 5-year survival of patients who
underwent a similar schedule of chemoradiation was 27%. The
majority of patients in this study had squamous carcinoma, and it
was not very clear how patients were selected for nonsurgical
treatment. In addition, staging investigations would be considered
suboptimal by today’s standards.
In the US Intergroup Study, the two cycles of nonconcurrent
chemotherapy were given after chemoradiation, and only about
half the patients were able to complete this phase of therapy. By
giving these cycles in the neoadjuvant setting, treatment can start
straight away and patient’s dysphagia is often improved prior to
the RT. It was hoped in our current protocol that this would be
more a more tolerable strategy for delivering additional systemic
therapy. In addition, protracted venous infusional (PVI) 5FU was
used. This has been shown to be superior to bolus treatments in
other cancers (Meta-analysis Group, 1998) and optimises the
radio-sensitising properties of this drug, which has a short half-
life. Although, in our study, chemotherapy modifications were
required in 37% of patients, the great majority of these were due to
troublesome rather than life-threatening toxicities, and indeed
93% of the overall planned chemotherapy dose was delivered.
In a similar number of patients, Sykes et al (1998) demonstrated
that, in carefully selected patients, long-term survival can be
achieved using the radiation-based therapy. As in our series,
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Figure 3 Overall survival of patients according to the stage of primary
oesophageal tumour (T stage).
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Figure 2 Overall survival of patients according to Group Stage of
disease. Stage I and II (T1N0, T2-3N0, T12N1), Stage III (T3N1, T4N0-1),
Stage IVa (M1a disease).
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Figure 1 Overall survival of 90 patients receiving definitive chemoradia-
tion for inoperable oesophageal cancer.
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lpatients were selected because they were not suitable for surgery.
However, although EUS was not available, the majority of patients
had tumours less than 5cm in length, which is associated with a
significantly reduced risk of mediastinal lymphadenopathy, and
over 90% of cases had squamous carcinomas. There were
significantly more adenocarcinomas in our series and the mean
length of tumour was 6.9cm (mean RT field length 14.1cm). This
makes direct comparisons difficult, but the better outcome in
median, 2-, 3- and 5-year survival may be due to the superiority of
chemoradiation over RT alone.
How do these results compare to surgical series? There have
recently been two large multicentred randomised controlled trials
evaluating the role of chemotherapy prior to surgery. The UK MRC
OE02 trial demonstrated a clear benefit for neoadjuvant treatment
(Medical Research Council Oesophageal Cancer Working Group,
2002). The overall survival at 2 years was significantly increased
from 35 to 44%, and median survival from 13.4 to 17.6 months in
favour of preoperative chemotherapy. In the US Intergroup 0116
trial, there was no statistical difference in overall survival, 2-year
and median survivals being approximately 35% and 15.5 months,
respectively (Kelsen et al, 1998). These are probably the most
reliable results to benchmark outcome from modern surgical
intervention. We report a 2-year survival of 51% and a median
survival of 26 months. While it is necessary to be cautious when
comparing retrospective series with randomised trial data, it is
worth noting that, in our series, all patients were considered not
suitable candidates for surgery because of adverse factors relating
to the patients or their disease. This group of patients therefore fall
into a poor prognostic group; indeed, previously many would have
been considered only for palliative therapy.
There was a highly significant difference in outcome between
those who did not receive surgery due to characteristics relating to
the patients, for example, co-morbidity, performance status,
patient choice, etc, compared with factors relating to their disease,
for example, invasion of mediastinal organs, extensive lymphade-
nopathy, etc., (Po0.001, Figure 4). Many patients with oesopha-
geal cancer have chronic co-morbidity because of shared
aetiological factors, namely chronic obstructive pulmonary dis-
ease, ischaemic heart disease and age. While these may increase
the risks of surgery prohibitively, they need not be immediately life
threatening. Contrasting with this, those patients considered
unresectable usually had disease overtly infiltrating other med-
iastinal organs, namely the aorta, trachea or pleura, or extensive/
bulky lymphadenopathy. Although these patients may have some
initial palliative benefit from definitive CRT, it will rarely achieve
long-term disease control. Indeed, Cox regression analysis
indicated nonindependence between tumour stage and the reason
for not having surgery, in terms of prognosis.
As expected, advancing stage of disease was generally associated
with a poorer outcome and patients with stage I or II disease had a
significantly better prognosis than patients with stage III and IV.
The reason why stage IVa (any T, any N, M1a) patients did not
show a significantly reduced survival rate than patients with stage
III (T3 N1 or T4 any N, M0) disease may be that the latter patients
had on average more bulky disease than the former. In this cohort,
all those with Stage IVa disease had nonbulky coeliac nodal
involvement with cancer in the lower on-third oesophagus (M1a
disease). This extent of disease may have a more favourable
outcome with or without therapeutic intervention than patients
with stage III disease not receiving surgery. Cox regression showed
that T4 disease had a greater impact on outcome than the presence
of M1a, and in stage III cases the proportion of T4 tumours was
higher (68%) than in stage IVa cases (32%).
Although chemoradiation is considered to be superior in terms
of local control and survival over RT alone, it is associated with
increased toxicity (Cooper et al, 1999; Wong et al, 2003). In the
current series, apart from admission to hospital for ‘hotel’ needs
and enteral feeding for malignant dysphagia, 19% of patients
required admission to hospital for treatment-related toxicity.
The majority of these admissions were for intravenous
rehydration as a result of oral mucositis, oesophagitis and
diarrhoea. As well as this, some patients felt extremely weak and
tired towards the end of treatment. This complex treatment should
only be undertaken where there is an experienced team. In our
centre, patients benefit from an upper GI specialist nurse, a
dedicated dietician, and a radiographer familiar with combined
chemoradiation regimens.
As well as the encouraging results with respect to overall
survival, it is also particularly encouraging that, several weeks after
completing this treatment, patients frequently feel very well and
most notably their dysphagia has usually resolved. This, and other
aspects of quality of life, is the subject of ongoing research by the
South East Wales Oesophago-Gastric Unit.
What proportion of patients may be suitable for this regimen? In
1995, an audit of all cases diagnosed with oesophagogastric cancer
in Wales found the incidence of oesophageal cancer to be 11/
100000 (Pye et al, 2001). Based upon this data, Velindre Cancer
Centre serving South East Wales with a population of 1.48 million
people would expect to see 165 patients per year with this disease.
In 2001, the most recent complete annual data available, 152
patients diagnosed with oesophageal cancer were referred for
consideration of treatment. Of these, 86 patients were treated with
palliative intent. Of the 66 cases that were thought suitable for
potentially curative therapy, the distribution of treatment mod-
alities used is shown in Table 4. On the basis of the most recent
data available, this therapy was given to 21% of all patients with
oesophageal cancer and 50% of those being treated with curative
intent. It is possible that a greater proportion of patients would
benefit from this treatment, particularly those patients currently
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Figure 4 Overall survival of patients according to the predominant
reason given for not undergoing surgery. Patient factors¼Co morbidity,
performance status and patient choice.
Table 4 Distribution of treatment modalities used for 66 cases of
oesophageal cancer treated with curative intent in 2001
Treatment modality Number (%)
Surgical-based therapy
Surgery alone 5 (7.5%)
Surgery+preoperative chemotherapy 10 (15%)
Surgery+preoperative chemoradiation 12 (18%)
Radiotherapy based therapy
Radiotherapy alone 6 (9%)
Chemoradiation 33 (50%)
Total 66
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surgical based treatment.
In the United States, results from the ‘Patterns of Care’ report
reflect that chemoradiation is already a standard treatment option
for patients with nonmetastatic disease (Coia et al, 2000). In all,
45% of the patients received CRT as their sole therapy, and in
32.8% this was with a RT dose of X50Gy. With increasing use of
this treatment, it is essential to optimise the delivery of this
therapeutic approach. Despite the encouraging survival rate in this
report, disease progression at the site of original disease is the
predominant pattern of treatment failure. Of 49 patients who
developed progressive disease, there was a failure to achieve local
control at the end of treatment in 17 cases and a further 21
developed evidence of local disease progression during follow-up.
Therefore, locoregional disease was a component of treatment
failure in 84% of cases, whereas metastatic disease was a
component in 22%. The overall local failure rate of 42% is similar
to other chemoradiation studies (Minsky et al, 2002), but possibly
higher than that seen after surgery (Kelsen et al, 1998; Dresner
et al, 2000).
Undoubtedly, the way to improve outcomes is through well-
conducted research. This disease site has been generally been poor
in recruitment of patients into clinical studies, whereas chemor-
adiation trials in other cancer sites such as anal cancer
demonstrate that high rates of accrual can be obtained (Anal
Cancer Trial Working Party, 1996). Evidence-based ‘best practice’
protocols need to evolve through collaboration between specialist
centres in the UK, where it can be shown that this complex therapy
can be delivered safely. Changing body contours and tissue
densities together with the close proximity of important normal
tissue structures make tumours of the oesophagus a challenging
disease in which to deliver a homogenous dose of radiation, and
therefore a prime tumour site in which to test innovative
technologies such as intensity-modulated radiotherapy (IMRT).
There is evidence for a radiation dose effect in this disease (Geh
et al, 2000), though attempts to increase the dose have not yet led
to an improved outcome (Minsky et al, 2002).
Capecitabine and oxaliplatin are being tested in advanced
oesophagogastric cancer and would certainly provide a more
convenient and hopefully more active systemic regimen. Irinote-
can and taxanes have also shown high activity in Upper GI
malignant disease, together with promising radiosensitising
properties.
These data show that definitive chemoradiation is feasible and
tolerable for 50% of patients with oesophageal cancer, treated with
potentially curative therapy. It supports other evidence that this
modality is the treatment of choice in patients unsuitable for
surgery on the basis of co-morbidity or locally advanced disease. It
also suggests that it should be compared in a prospective study to a
surgically based treatment strategy.
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